91,070 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by Algert Global LLC

Key Points

• Algert Global LLC acquired 91,070 shares of Supernus Pharmaceuticals in the second quarter, valued at approximately $4.24 million and representing about 0.16% of the company.
• Several other institutional investors also built positions, including BlackRock, which acquired a stake worth roughly $434.9 million, while Woodline Partners increased its holdings by 63.5%.
• Supernus reported quarterly revenue of $219.1 million, up 32.4% year over year and above estimates, but posted an EPS loss of $1.01 versus expectations for $0.42. The stock opened at $44.19, while analysts maintained a “Moderate Buy” consensus and an average price target of $62.83.

Algert Global LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 91,070 shares of the specialty pharmaceutical company's stock, valued at approximately $4,236,000. Algert Global LLC owned about 0.16% of Supernus Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SUPN. BlackRock Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $434,871,000. Rubric Capital Management LP acquired a new position in Supernus Pharmaceuticals in the 2nd quarter valued at about $21,908,000. Assenagon Asset Management S.A. purchased a new stake in Supernus Pharmaceuticals during the first quarter worth about $27,428,000. Woodline Partners LP increased its stake in Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company's stock worth $60,398,000 after purchasing an additional 490,835 shares during the period. Finally, Rice Hall James & Associates LLC acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $22,800,000.

Supernus Pharmaceuticals Stock Down 1.5%

SUPN opened at $44.19 on Friday. The firm has a market cap of $2.57 billion, a price-to-earnings ratio of -23.02, a price-to-earnings-growth ratio of 0.83 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 52 week low of $42.45 and a 52 week high of $59.68. The business's 50 day moving average is $46.83 and its two-hundred day moving average is $48.69.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. During the same quarter in the prior year, the company earned $0.40 EPS. The firm's revenue for the quarter was up 32.4% on a year-over-year basis. Equities analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on SUPN shares. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 6th. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a report on Thursday, July 9th. Wall Street Zen cut Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $62.83.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source